CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 65 enrolled
Drug / intervention
CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injectiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00361842
NCT00361842Phase 2Completed
CompareCT.gov

Multicenter, Open-Label, Phase 2 Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Carcinoma

Jazz Pharmaceuticals·interventional·Posted Aug 9, 2006·Updated Jul 2, 2021

In Brief

A Phase 2 clinical trial evaluating CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection for Colorectal Neoplasms. Completed, enrolled 65 participants across 13 sites in 2 countries.

Detailed Summary

The purpose of this study is to determine whether CPX-1 is effective in patients with advanced colorectal cancer who have already received chemotherapy that included the drug oxaliplatin or irinotecan. All patients will receive CPX-1 at a dose of 210 units/m2 over 90 minutes every two weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Neoplasms
CountriesCanada, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 9, 2006
Enrollment StartJul 1, 2006
Primary CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 19.9 years ago

Interventions

CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injectiondrug

CPX-1 Liposome Injection is a liposomal formulation of a fixed combination of the antineoplastic drugs irinotecan HCl and floxuridine.